Xinhua Pharmaceutical class 3.1 constipation treatment drug polycarboxylate non calcium completed the on-site inspection

According to the website of the State Food and Drug Administration (CFDA) on April 2, on-site inspection has been completed for polycarbonate non calcium tablets and APIs, a class 3.1 constipation treatment drug of Xinhua Pharmaceutical, and the review conclusion is waiting According to the new drug review process, it will be transferred to the drug review center for three in one comprehensive review, and the production approval document can be obtained after the CFDA signature is submitted According to the public information, polycarboxylate is a kind of 3.1 chemical medicine, which is an innovative constipation treatment drug with dual effects of constipation and diarrhea Compared with commonly used stimulant laxatives, salt laxatives, osmotic laxatives and lubricated laxatives, Xinhua medicine pointed out that polycajaro calcium has the advantages of water retention, gelation, absorption in the body, no influence on intestinal flora, and no effect on receptors, enzymes and so on According to the CFDA website information, at present, only Suzhou Sinochem Pharmaceutical Industry Co., Ltd has the production approval documents of the drug preparation Xinhua Pharmaceutical is the largest production and export base of antipyretic and analgesic drugs in China In recent years, the company has increased investment in research and development from APIs to preparations Polycarbo non calcium is one of the core products currently reserved by the company.